AGN traded at a 100 million market cap after safety clearance in humans. NYR are 2-3 weeks away from final cohorts being cleared and announced, has the same main mechanism of action as AGN with NYR having additional indications. NYR in plans for a quick phase 2a already and AGN is about to rerate towards a 300-400 million market cap as they are expected to receive a licence agreement bigger than Aptoll
Aptoll a 2 billion dollar license agreement with a 200 million dollar upfront payment on a 5-15 percent reduction in brain injury after phase 2a. Drug companies will be taking over these cocktail of drugs
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.03M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1642 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 682527 | 2 |
View Market Depth
| Last trade - 14.40pm 31/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |
Day chart unavailable